Qing‐Bai She
Impact in
- Molecular Biology top 1%
- PI3K/AKT/mTOR signaling in cancer
- Melanoma and MAPK Pathways
- Protein Kinase Regulation and GTPase Signaling
- Cell death mechanisms and regulation
- Cancer Research top 2%
Papers in
- Co-authors
- David B. SolitNeal RosenZigang DongNanyue ChenDale L. LudwigHeidi A. LaneGordon B. MillsFrancesco Hofmann
- Journals
- Cancer Research (11 papers)Journal of Biological Chemistry (4 papers)Oncogene (4 papers)Nature Communications (3 papers)FEBS Letters (3 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Qing‐Bai She
71 papers receiving 6.5k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Molecular Biology 5.0k
- Cancer Research 999
- Oncology 1.8k
- Geriatrics and Gerontology 244
- Pathology and Forensic Medicine 786
Countries citing papers authored by Qing‐Bai She
This map shows the geographic impact of Qing‐Bai She's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qing‐Bai She with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qing‐Bai She more than expected).
Fields of papers citing papers by Qing‐Bai She
This network shows the impact of papers produced by Qing‐Bai She. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qing‐Bai She. The network helps show where Qing‐Bai She may publish in the future.
Co-authors
The 25 scholars most cited alongside Qing‐Bai She, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 8 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 79 | |
| 6 | 2021 | 1 | |
| 7 | Scade2Nu : A Tool for Verifying Safety Requirements of SCADE Models with Temporal Specifications. | 2019 | 1 |
| 8 | 2018 | 24 | |
| 9 | 2013 | 143 | |
| 10 | 2011 | 88 | |
| 11 | 2010 | 133 | |
| 12 | 2010 | 53 | |
| 13 | Muc16 carboxyl portion expression alternates PI3K/Akt and EGFR/HER2/ERK signal pathways in human ovarian cells | 2008 | 1 |
| 14 | mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Hit paper breakdown → | 2006 | 2037 |
| 15 | Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. | 2003 | 244 |
| 16 | 2002 | 84 | |
| 17 | 2001 | 72 | |
| 18 | 2000 | 12 | |
| 19 | 1999 | 6 | |
| 20 | 1995 | 21 |
About Qing‐Bai She
Qing‐Bai She is a scholar working on Toxicology, Geriatrics and Gerontology, Molecular Biology, Biotechnology and Cancer Research, having authored 73 papers that have together received 6.6k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (21 papers), Protein Kinase Regulation and GTPase Signaling (9 papers), Melanoma and MAPK Pathways (8 papers), Cancer-related Molecular Pathways (6 papers), Polyamine Metabolism and Applications (5 papers), Folate and B Vitamins Research (4 papers), Invertebrate Immune Response Mechanisms (3 papers) and Galectins and Cancer Biology (3 papers). The work is most often cited by research in Molecular Biology (5.0k citations), Cancer Research (999 citations), Oncology (1.8k citations), Geriatrics and Gerontology (244 citations) and Pathology and Forensic Medicine (786 citations). Qing‐Bai She has collaborated with scholars based in United States, China and Japan. Frequent co-authors include David B. Solit, Neal Rosen, Zigang Dong, Nanyue Chen, Dale L. Ludwig, Heidi A. Lane, Gordon B. Mills, Francesco Hofmann, Daniel J. Hicklin and José Baselga. Their work appears in journals such as Cancer Research, Journal of Biological Chemistry, Oncogene, Nature Communications and FEBS Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.